Zika Virus Infection Clinical Trial
Official title:
A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated ZIKV vaccine. Each dose will be administered intramuscularly (i.m.) in the deltoid muscle on Days 0 and 28. In addition, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04697147 -
Zika and Neurodevelopment Among Infants in Grenada
|
N/A | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Completed |
NCT02952833 -
ZIKA Vaccine in Naive Subjects
|
Phase 1 | |
Terminated |
NCT03055585 -
Applying Wolbachia to Eliminate Dengue
|
N/A | |
Not yet recruiting |
NCT05589012 -
Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
|
||
Completed |
NCT02963909 -
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
|
Phase 1 | |
Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
Recruiting |
NCT06334393 -
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
|
Phase 1 | |
Terminated |
NCT03161444 -
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
|
N/A | |
Completed |
NCT03008122 -
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area
|
Phase 1 | |
Completed |
NCT04478656 -
Safety and Immunogenicity of BBV121
|
Phase 1 | |
Completed |
NCT03624946 -
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
|
Phase 1 | |
Completed |
NCT03330600 -
Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
|
N/A | |
Completed |
NCT05041439 -
Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico
|
N/A | |
Recruiting |
NCT03255369 -
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
|
||
Completed |
NCT03206541 -
Neurologic Manifestations of the Arbovirus Infection in Colombia
|
||
Completed |
NCT04033068 -
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
|
Phase 1 | |
Completed |
NCT03679728 -
Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection
|
||
Completed |
NCT03776903 -
Evaluation of the Clinical Performance of the ZIKV Detectâ„¢ 2.0 IgM Capture ELISA
|
||
Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|